GENE ONLINE|News &
Opinion
Blog

2022-05-05| Trials & Approvals

FDA Greenlights First In-Vitro Alzheimer’s Diagnostic

by Fujie Tham
Share To

The U.S. Food and Drug Administration (FDA) authorized marketing for the first in-vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease, eliminating the need for time-consuming and expensive PET scans, with test results available on the same day. 

Lumipulse G β-Amyloid Ratio (1-42/1-40) test by Fujirebio Diagnostics taps the unmet demand for a reliable and safe test that can accurately identify patients with amyloid plaques associated with Alzheimer’s disease. Previously, doctors relied on positron emission tomography (PET) scans to detect amyloid plaques in patient’s brain to diagnose Alzheimer’s disease before symptoms occur.

Related Article: Biogen Halts Aduhelm’s Second EU Marketing Application

 

Detecting Amyloid Plaques from Cerebral Spinal Fluid

 

Alzheimer’s disease (AD) is the most common neurodegenerative disease with more than 40 million cases reported worldwide, characterized by the aggregation of the beta-amyloid proteins in the Alzheimer’s brain, abnormal levels of this naturally occurring protein clump together to form plaques that disrupt brain cell function.

In the race to detect the disease earlier and begin treatments sooner, this in-vitro assay measures amyloid plaque concentration in the cerebral spinal fluid (CSF), serving as another more accessible diagnosis tool. The FDA reports that it evaluated the safety and efficacy of the test in a clinical study of 292 CSF samples from the Alzheimer’s Disease Neuroimaging Initiative sample bank.

“With the Lumipulse test, there is a new option that can typically be completed the same day and can give doctors the same information regarding brain amyloid status, without the radiation risk, to help determine if a patient’s cognitive impairment is due to Alzheimer’s disease,” said Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health.

This decision follows around one year after FDA authorized Biogen’s Alzheimer’s disease therapy Aduhelm (aducanumab) based on a reduction in brain amyloid plaque

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
FDA Finds Carcinogen In Merck’s Diabetes Drug, Allows Continued Sales To Avoid Shortage
2022-08-11
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!